Akoya Biosciences Inc. said an in-depth comparison of immuno-oncology biomarker types determined that multiplex immunofluorescence with spatial characterization significantly outperformed other biomarker testing approaches for predicting patient response to treatments targeting PD-1/PD-L1.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
